Agios Pharmaceuticals
AGIO
189 hedge funds and large institutions have $2.01B invested in Agios Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 54 reducing their positions, and 31 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 54
2.01% more ownership
Funds ownership: 103.34% → 105.35% (+2%)
3% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 31
0% more funds holding
Funds holding: 189 → 189 (0)
34% less capital invested
Capital invested by funds: $3.03B → $2.01B (-$1.02B)
75% less call options, than puts
Call options by funds: $8.62M | Put options by funds: $35.1M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$56.8M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$34.9M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$18.4M |
| 4 |
CC
Casdin Capital
New York
|
+$18.2M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$60M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$23.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$20.5M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$14.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.4M |
AGIO Hedge Fund Activity: Q3 2019 in Review
189 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2019, worth a combined $2.01B — down 34% from $3.03B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AGIO positions and 31 closed out — a net gain of 1 holder — while 73 added to existing stakes and 54 trimmed.
The largest buyer was Capital International Investors, adding an estimated $56.8M. The largest seller was BlackRock, cutting an estimated $60M.
- 189 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $2.01B of Agios Pharmaceuticals stock for Q3 2019, down 34% quarter-over-quarter.
- 32 funds opened new Agios Pharmaceuticals positions in Q3 2019 and 31 closed out, a net change of +1 holder.
- The largest Agios Pharmaceuticals buyer in Q3 2019 was Capital International Investors, an estimated $56.8M added.
- The largest Agios Pharmaceuticals seller in Q3 2019 was BlackRock, an estimated $60M sold.
Based on aggregated 13F filings for Q3 2019.